The application of high throughput screening techniques and computational chemistry has resulted in a marked shift in drug candidates with identified therapeutic potential, increasing the prevalence of BCS Class II and IV compounds. Faced with a growing need to effectively develop these drugs, formulators are becoming increasingly reliant on more complex and sophisticated strategies. The intensifying requirement to effectively formulate Class II and IV drugs increases the need to optimise analytical strategies. Jamie Clayton at Freeman Technology considers the value of powder rheometry within this context, focusing on its ability to support innovative product development.